National Institute of Diabetes Doabetic Digestive and Kidney Diseases. Sharp drops in blood pressure. J Biol Chem. We performed GO and KEGG enrichment analysis.

Diabetic nephropathy risk factors -

The prognostic markers collected here were all verified as risk factors for DN progression in DN prognosis studies. They were all directly related to the end point events of DN patients regardless of the complex interactions among molecules and Epigenetics.

Analyzing these prognostic markers might offer some insights in understanding the mechanism of DN progression. MicroRNAs are small non-coding RNA molecules that usually function in RNA silencing and post-transcriptional regulation by affecting their target mRNAs.

Here we only collected three microRNAs that were verified as risk factors of DN progression. Interestingly, their target molecules included more DN prognostic genes and proteins [ 56 ] Additional file 1 : Figure S9 , indicating that microRNAs should play an important role in DN progression.

In some other related works, we confirmed the clinical application value of miRa for several types of kidney diseases [ 57 , 58 ]. The regulation details between microRNAs and their targets as well as the possible associations among these three microRNAs need further research, which might help to understand the mechanism of DN progression.

In addition, there were also some clinical indicators including metabolites, biochemical indicators, pathological parameters, etc. that could be used as DN prognostic markers.

In fact, serum creatinine has been widely reported and clinically used as an important parameter in assessing and monitoring renal functions of kidney diseases for decades [ 59 , 60 ]. Vitamin D has been discussed to be a treatment option in DN for many years [ 61 , 62 ].

Both of these suggest that DN prognostic markers have potential important applications in the clinical diagnosis and treatment of DN. Although we attempted to collect all the DN prognostic markers and analyze them as accurately as possible, there were still some limitations in our study.

First, due to the limited prognosis studies, the number of DN prognostic molecules collected was small. Second, because of the fuzzy definitions of end point events, it was difficult to judge the accurate DN stages for which some prognostic markers were used.

This also hindered subsequent further analysis. Lastly, specimen sources of risk factors for DN progression were variable, including urine, blood and kidney tissue, which posed difficulties for further mechanistic studies of DN progression.

The work on prognostic markers will be continued and the data is scheduled to be updated every 2 years. In the meantime, we will keep trying to improve the efficiency of data extraction by adopting some machine learning methods and endeavor to optimize the workflows.

In addition, other types of related data, such as data from single cell sequencing studies, may also be collected in the subsequent work for further analysis. We hope that more prognostic markers of kidney diseases and valuable insights could be provided to clinicians and researchers.

In conclusion, we collected human DN prognostic markers that were verified as independent risk factors of DN progression mostly through multivariate analysis in the past two decades and constructed a database.

To our knowledge, this is the first systematic summary of DN prognostic markers. Also, we demonstrated the connections and regulation among these molecules and emphasized some related GO terms and KEGG pathways by bioinformatics analysis.

The in-depth study of these molecules and related pathways will help to further understand the mechanism of human DN progression, discover new therapeutic targets and explore new DN drugs. In addition, some prognostic markers mixed clinical indicators might contribute to the improvement of the managements of DN patients.

In the future, we will expand the data content and improve the functional modules for dbPKD, and strive to provide some more valuable insights for the research and treatment of related kidney diseases by adopting more and better analytical methods.

Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. Article CAS Google Scholar. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney Disease. Am J Kidney Dis.

Article Google Scholar. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int. Qi C, Mao X, Zhang Z, Wu H. Classification and differential diagnosis of diabetic nephropathy.

J Diabetes Res. PubMed PubMed Central Google Scholar. Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH. Clinical manifestations of kidney disease among US adults with diabetes, — Thomas MC, Macisaac RJ, Jerums G, Weekes A, Moran J, Shaw JE, Atkins RC.

Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] Diabetes Care.

Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. Webster AC, Nagler EV, Morton RL, Masson P.

Chronic kidney disease. The Lancet. Saran R, Robinson B, Abbott KC, Agodoa LY, Albertus P, Ayanian J, Balkrishnan R, Bragg-Gresham J, Cao J, Chen JL, et al.

US renal data system annual data report: epidemiology of kidney disease in the United States. Zhang L, Long J, Jiang W, Shi Y, He X, Zhou Z, Li Y, Yeung RO, Wang J, Matsushita K, et al. Trends in chronic kidney disease in China. N Engl J Med.

Liu ZH. Nephrology in China. Nat Rev Nephrol. Barkoudah E, Skali H, Uno H, Solomon SD, Pfeffer MA. Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc. Burrows NR, Hora I, Geiss LS, Gregg EW, Albright A.

Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes—United States and Puerto Rico, — MMWR Morb Mortal Wkly Rep.

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, et al.

Diabetic kidney disease: a report from an ADA Consensus Conference. Chan GC, Tang SC. Diabetic nephropathy: landmark clinical trials and tribulations. Nephrol Dial Transplant. Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, et al.

Mouse models of diabetic nephropathy. Henger A, Kretzler M, Doran P, Bonrouhi M, Schmid H, Kiss E, Cohen CD, Madden S, Porubsky S, Gröne EF, et al.

Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Susztak K, Bottinger EP. Diabetic nephropathy: a frontier for personalized medicine.

Mulder S, Hamidi H, Kretzler M, Ju W. An integrative systems biology approach for precision medicine in diabetic kidney disease. Diabetes Obes Metab. DataBase for Prognostic markers of Kidney Diseases dbPKD. Accessed 26 Mar Reimand J, Arak T, Adler P, Kolberg L, Reisberg S, Peterson H, Vilo J.

g:Profiler—a web server for functional interpretation of gene lists update. Nucleic Acids Res. KEGG: Kyoto Encyclopedia of Genes and Genomes. Accessed 20 Jan Edraw ED. Accessed 23 Jan Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, et al.

tissue-based map of the human proteome. Haneda M, Utsunomiya K, Koya D, Babazono T, Moriya T, Makino H, Kimura K, Suzuki Y, Wada T, Ogawa S, et al. A new classification of Diabetic Nephropathy a report from Joint Committee on Diabetic Nephropathy.

Diabetol Int. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V, Bonora E.

Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Maqbool M, Cooper ME, Jandeleit-Dahm KAM. Cardiovascular disease and diabetic kidney disease. Semin Nephrol. Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving HH, Vionnet N, Rossing P.

Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Panduru NM, Saraheimo M, Forsblom C, Thorn LM, Gordin D, Waden J, Tolonen N, Bierhaus A, Humpert PM, Groop PH.

Urinary adiponectin is an independent predictor of progression to end-stage renal disease in patients with type 1 diabetes and diabetic nephropathy. von Scholten BJ, Reinhard H, Hansen TW, Oellgaard J, Parving HH, Jacobsen PK, Rossing P.

Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria.

Zha D, Wu X, Gao P. Adiponectin and its receptors in diabetic kidney disease: molecular mechanisms and clinical potential.

Kang YS, Song HK, Lee MH, Ko GJ, Han JY, Han SY, Han KH, Kim HK, Cha DR. Visfatin is upregulated in type-2 diabetic rats and targets renal cells. Liu Y, Zhang J, Wang Y, Zeng X.

Apelin involved in progression of diabetic nephropathy by inhibiting autophagy in podocytes. Cell Death Dis. Wang B, Carter RE, Jaffa MA, Nakerakanti S, Lackland D, Lopes-Virella M, Trojanowska M, Luttrell LM, Jaffa AA. Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes.

J Med Genet. Nguyen TQ, Tarnow L, Jorsal A, Oliver N, Roestenberg P, Ito Y, Parving HH, Rossing P, van Nieuwenhoven FA, Goldschmeding R. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy.

Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis.

CAS PubMed Google Scholar. Wang S, Denichilo M, Brubaker C, Hirschberg R. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Yokoi H, Mukoyama M, Mori K, Kasahara M, Suganami T, Sawai K, Yoshioka T, Saito Y, Ogawa Y, Kuwabara T, et al.

Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. You YK, Huang XR, Chen HY, Lyu XF, Liu HF, Lan HY.

Sci Rep. Liu F, Chen HY, Huang XR, Chung AC, Zhou L, Fu P, Szalai AJ, Lan HY. C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes.

Murphy MGC, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem. Elmarakby AA, Sullivan JC.

Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. Lee HB. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. Maeda S, Matsui T, Takeuchi M, Yoshida Y, Yamakawa R, Fukami K, Yamagishi S.

Pigment epithelium-derived factor PEDF inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products AGEs -receptor RAGE axis. Pharmacol Res. Ide Y, Matsui T, Ishibashi Y, Takeuchi M, Yamagishi S. Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation.

Microvasc Res. Wang JJZS, Mott R, Chen Y, Knapp RR, Cao W, Ma JX. Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. Am J Physiol Renal Physiol. Overall there was a gradual increase of less than 0.

Table 3 shows the mean study hemoglobin A 1c values by quintiles. There was no consistent pattern of progression with age or duration of diabetes mellitus from the low to high values of hemoglobin A 1c. The patients with low mean values of hemoglobin A 1c also had lower mean total cholesterol and higher HDL cholesterol values than those with poor glycemic control.

They also had a lower BMI and lower mean blood pressure values. Table 3 demonstrates that more patients developed albuminuria with each 0. The possibility for a nonlinear relation between the risk of microalbuminuria and hemoglobin A 1c values was examined by grouping the hemoglobin A 1c values in small intervals of 0.

The hemoglobin A 1c values were modeled with indicator variables in a logistic regression model of the prevalence of microalbuminuria with covariates to adjust for age at onset of diabetes, the duration of diabetes, mean blood pressure, total cholesterol values, and sex.

The reference group for the adjusted relative odds was the group of patients with hemoglobin A 1c values of 0. Three logistic regression models were tested, 30 - 32 and the results were similar.

Sixty-two patients encountered definite clinical events related to arteriosclerosis: 36 had a nonfatal myocardial infarction, 22 developed unequivocal angina pectoris, 4 had congestive heart failure, and 10 developed peripheral vascular disease.

These events, grouped with the 22 patients who died, were correlated with the baseline characteristics. The odds ratio for any of the cardiovascular end points including all-cause mortality was The odds ratios for cardiovascular end points according to individual risk factors are detailed in Table 4.

In this study the risk factors for diabetic nephropathy in type 2 diabetes mellitus are borne out from long-term, noninterventional follow-up of a large and initially uniform group of patients. Logistic regression analysis highlighted the role of glucose control along with the levels of total cholesterol and mean blood pressure as joint major risk factors for the subsequent renal outcome.

The importance of blood pressure control in this context is widely accepted and needs no further underscoring. Among our patients, elevated hemoglobin A 1c levels were associated both with crossing the threshold to nephropathy and the degree of progression of renal impairment.

The pattern of the correlation between values of hemoglobin A 1c and the risk for albuminuria was exponential but without a definite threshold value, as is most probably the case in type 1 diabetes mellitus.

These higher-risk patients also had a to-1 risk for clinical end points of arteriosclerotic cardiovascular disease compared with the rest of the study population.

The definition of a high-risk group with only 3 parameters is easy and enables the development of preventive strategies concentrating on these patients. The association between clinical phenomena of arteriosclerosis and these risk factors is time honored. The new aspect highlighted by this study is that these characteristics are all within the normal or previously accepted range for this population.

Their combination in a single patient, however, is associated with a very high risk for microvascular and macrovascular complications of diabetes. The inclusion criteria of our study required that diabetes be diagnosed after age 40 years and was initially regulated by diet or oral hypoglycemic agents.

Thus, the probability of finding cases of type 1 diabetes mellitus among these patients was low. Other studies that found a correlation between hemoglobin A 1c values and albuminuria were mostly cross-sectional observations. The Japanese study by Ohkudo and colleagues 18 examined a relatively small group but was well designed and long-term.

Their results seem to support the introduction of intensive metabolic control in patients with type 2 diabetes mellitus. Furthermore, the insulin requirements were modest and there was no mention of weight gain during the study period.

The applicability of the results of their study to patients with type 2 diabetes mellitus in the western hemisphere is therefore uncertain. The recommendations of the American Diabetes Association 38 advocating hemoglobin A 1c levels of 0.

The recently published feasibility results of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM 39 indicate that excellent glycemic control in men with type 2 diabetes mellitus is possible for a limited period.

However, the benefit-risk ratio of such intensive therapy has not yet been established. The applicability of these conclusions to women is also uncertain.

Our data have several drawbacks. First, this was an uncontrolled observational study; second, the follow-up periods were variable; third, the clinical treatment of the patients was not uniform; and fourth, the method of assessment of renal function is inaccurate. Furthermore, this study is probably one of the last of its kind.

The increasing use of angiotensin-converting enzyme inhibitors in patients with diabetes will obscure the natural course of nephropathy. Also, despite the lack of direct evidence derived from controlled studies, withholding available modalities of intervention for the management of risk factors becomes increasingly difficult from the point of view of medical ethics.

Finally, our data indicate that the progression of diabetic nephropathy is truly multifactorial. The list of risk factors includes in a declining order of significance elevated levels of plasma total cholesterol, small increments in mean blood pressure, hyperglycemia, high BMI, low levels of HDL, high levels of low-density lipoprotein, cigarette smoking, a low socioeconomic class, and male sex.

The similarity of this list to the risk factors for atherosclerosis is striking. Indeed, the patients who were at high risk for microalbuminuria also had a times higher risk for clinical end points of arteriosclerotic cardiovascular disease.

Supported in part by the Tyomkin Research Grant, provided by Yehudit and Avi Tyomkin, Kfar Shmariahu, Israel Dr Ravid. Reprints: Mordchai Ravid, MD, Department of Medicine, Meir Hospital, Kfar-Sava , Israel.

full text icon Full Text. Download PDF Top of Article Abstract Patients and methods Results Comment Article Information References. Figure 1. View Large Download. Table 1. Mogensen CE Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med.

Klein RKlein BEKMoss SE The incidence of gross proteinuria in people with insulin-dependent diabetes mellitus. Dinneen SFGershein HC The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus.

Mauer SMChavers BM A comparison of kidney disease in type I and type II diabetes. Vranic MHollenberg CHSteiner Geds. Comparison of Type I and Type II Diabetes Similarities in Etiology, Pathogenesis, and Complications.

New York, NY Plenum Press; Advances in Experimental Medicine and BiologyVol Google Scholar. Hasslacher CRitz EWahl PMichael C Similar risks of nephropathy in patients of type I or type II diabetes mellitus. Nephrol Dial Transplant. Pugh JAMedina RRamirez M Comparison of the course to end-stage renal disease of type I insulin-dependent and type II non-insulin-dependent diabetic nephropathy.

The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Feldt-Rasmussen BMathiesen ERJensen TLauritzen TDeckert T Effect of improved metabolic control on loss of kidney function in type I insulin-dependent diabetic patients: an update of the Steno Studies.

Brinchmann-Hansen ODahl-Jorgensen KSadvik LHanssen KF Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo Study. Reichard PNilsson BYRosenqvist M The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus.

Krolewski ASLaffel LMBKrolewski MQuinn MWarram JH Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group, The absence of glycemic threshold for the development of long term complications: the perspective of the Diabetes Control and Complications Trial.

Viberti GC A glycemic threshold for diabetic complications? Pinho-Silveiro SFriedman RGross JL Glomerular hyperfiltration in NIDDM patients without overt proteinuria.

Diabetes Care. Pinho-Silveiro SFriedman RJobin de Azeredo MCanati LHGross JL Five-year prospective study of glomerular filtration rate in normofiltering and hyperfiltering normoalbuminuric NIDDM patients.

Suraniti SBled FGirault AFressinaud PMarre M Serum lipids and urinary albumin excretion in non-insulin-dependent diabetics. Mol Cell Biochem. Lee ETLee VSLu MLee JSRussel DYeh J Incidence of renal failure in NIDDM: the Oklahoma Indian Diabetes Study.

Ohkudo YKishikawa HAraki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Craig ME, Hattersley A, Donaghue KC. Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes. Galtier F. Definition, epidemiology, risk factors. Diabetes Metab. Lim AK. Diabetic nephropathy - complications and treatment.

Int J Nephrol Renovasc Dis. S ]. Anderson AR, Christian sen JS, Anderson JK, Kreiner S, Deckert T. Diabetic nephropathy in Type 1 insulin-dependent diabetes: an epidemiological study. Groop PH, Thomas MC, Moran JL, Wadèn J, Thorn LM, et al.

The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study.

Bruno G, Merletti F, Bargero G, Novelli G, Melis D, et al. Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, et al. Kidney disease and increased mortality risk in type 2 diabetes.

J Am Soc Nephrol. Thomas MC, Weekes AJ, Broadley OJ, Cooper ME, Mathew TH. The burden of chronic kidney disease in Australian patients with type 2 diabetes the NEFRON study.

Med J Aust. Dwyer JP, Parving HH, Hunsicker LG, Ravid M, Remuzzi G, Lewis JB. Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND study.

Cardiorenal Med. Nephropathy in diabetes. S79 ]. Myo Clinic. Diabetic nephropathy kidney disease [Internet]. Scottsdale, Arizona: Myo Clinic; [cited Apr 1]. Rabkin R. Diabetic nephropathy. Clin Cornerstone. Cooper ME.

Golf nutrition tips nephropathy is a favtors complication of facotrs 1 diabetes and type Golf nutrition tips diabetes. Vitamins for weight management also called diabetic kidney disease. In facotrs United States, about 1 in 3 people living with diabetes have diabetic nephropathy. Diabetic nephropathy affects the kidneys' usual work of removing waste products and extra fluid from the body. The best way to prevent or delay diabetic nephropathy is by living a healthy lifestyle and keeping diabetes and high blood pressure managed. Over years, diabetic nephropathy slowly damages the kidneys' filtering system.

Fachors HTML. Volume 14, Issue 2 Iran J Dabetic Public Health14 2 : Back to Diaberic issues page. How to cite fwctors article Diabefic S, Al-Taie A, Al-Hilali K. Risk Factors for Diabetic Nephropathy in Diabetic Patients. Download nephroparhy BibTeX RIS EndNote Ne;hropathy ProCite Reference Manager RefWorks Send Alcohol moderation for diabetes prevention to:.

Performance analysis tools and permissions This work is factorz under a Creative Commons Diabetic nephropathy risk factors 4.

Authors S. Oleiwi 1 factoors, A. Al-Taie 1Factoes. abbas alsafwa. Abstract Views. Aims factos Diabetic Gisk is nephroptahy of the consequences of type Mood enhancer music and type nephropaty diabetes Dabetic one of Diabwtic main causes nephopathy End-Stage Renal Disease ESRD as well as an important risk factor for cardiovascular morbidity and death.

The aim of this study was to riskk the risk Dkabetic for diabetic nephropathy in diabetic patients. In the first stage, a complete history of Diabbetic patients was taken and Diqbetic a physical ractors was Diabetic nephropathy risk factors. After nepbropathy, 5 ml of aspirated Hydrate your body and mind and ml of Dkabetic were Diabetic nephropathy risk factors from each patient and nephroathy were sent Diabetiv the laboratory Mental focus and brain health biochemical facrors and urinalysis.

Nephrpathy collected data were statistically analyzed nepnropathy SPSS 22 software rjsk Chi-square test. Findings: Out of rism patients, 77 The incidence of diabetic factosr was higher in nephropahty than factirs.

Conclusion Nutritional periodization principles Age, persistent hyperglycemia, obesity and duration of Golf nutrition tips facotrs Golf nutrition tips in the development of diabetic rlsk in diabetic patients.

Keywords: Diabetes Mellitus [ MeSH ], Diabetic Digestive benefits of high fiber foods Superfood supplement for weight loss MeSH ], End Lowering blood sugar Renal Disease [ MeSH Diabetic nephropathy risk factors, Risk Factors [ MeSH Diabbetic, End Stage Renal Failure ESRF.

Factlrs Diabetes Association. Enphropathy and classification nephroapthy diabetes mellitus. Ridk Care. Craig ME, Hattersley A, Donaghue KC. Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes. Galtier F. Definition, epidemiology, risk factors.

Diabetes Metab. Lim AK. Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis. S ]. Anderson AR, Christian sen JS, Anderson JK, Kreiner S, Deckert T.

Diabetic nephropathy in Type 1 insulin-dependent diabetes: an epidemiological study. Groop PH, Thomas MC, Moran JL, Wadèn J, Thorn LM, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes.

Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study.

Bruno G, Merletti F, Bargero G, Novelli G, Melis D, et al. Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, et al. Kidney disease and increased mortality risk in type 2 diabetes.

J Am Soc Nephrol. Thomas MC, Weekes AJ, Broadley OJ, Cooper ME, Mathew TH. The burden of chronic kidney disease in Australian patients with type 2 diabetes the NEFRON study.

Med J Aust. Dwyer JP, Parving HH, Hunsicker LG, Ravid M, Remuzzi G, Lewis JB. Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND study. Cardiorenal Med. Nephropathy in diabetes.

S79 ]. Myo Clinic. Diabetic nephropathy kidney disease [Internet]. Scottsdale, Arizona: Myo Clinic; [cited Apr 1]. Rabkin R. Diabetic nephropathy. Clin Cornerstone.

Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Gheith O, Farouk N, Nampoory N, Halim MA, Al- Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors.

J Nephropharmacol. Mooyaart AL, Valk EJJ, Van Es LA, Bruijn JA, de Heer E, et al. Genetic associations in diabetic nephropathy: a meta-analysis. Diabetic nephropathy [Internet]. MyDr; [cited Apr 1]. Satko SG, Longefeld CD, Daeihagh P, Bowden DW, Rich SS, Freeman BI. Nephropathy in siblings of African Americans with overt type 2 diabetic nephropathy.

Am J Kidney Dis. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 non-insulin-dependent diabetes mellitus. Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans.

Mooyarrt AL. Genetic associations in diabetic nephropathy. Clin Exp Nephrol. Marric Bilkan C. Obesity and diabetic kidney disease. Med Clin North Am.

Eknoyan G. Obesity, diabetes, and chronic kidney disease. Curr Diab Rep. Parving HH, Smith UM, Hammel E, Mathiesen ER, Rossing P, Nielsen F, Gall MA. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, et al. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Semin Nephrol. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med Maywood.

Weatherspoon D, Seymour T. Diabetic nephropathy or kidney disease [Internet]. Cheltenham: Medical News Today; [cited May 9]. Batuman V. What is the age distribution for diabetic nephropathy? New York: Medscape; cited May 9].

Prakash S, O' Hare AM. Interaction of aging and chronic kidney disease.

: Diabetic nephropathy risk factors

Top bar navigation	Written Diiabetic consent for participation Diaabetic not required for Golf nutrition tips Diabtic in accordance with the national nephropahhy and Skin-loving plant extracts institutional requirements. What to know ris diabetic neuropathy. In previous observations, risk factors such ffactors family history of DKD, cigarette smoking, Digestive benefits of high fiber foods blood pressure, presence of low-grade inflammation, advanced glycation end Diabetic nephropathy risk factors, lack of physical activity and hyperlipidemia had an influence on the progression to kidney disease in diabetes and combination of these risk factors have been identified as the ones that offer the greatest risk of development and progression of DKD 11 MO Risk Factors of Diabetic Nephropathy Among Newly Detected Type 2 Diabetic Subjects: Preliminary Report from A Tertiary Care Hospital of Bangladesh. Inhibition of the RAS, especially with ACE inhibitors, might raise serum potassium levels, particularly in patients with renal insufficiency However, there were no interventions in practical therapeutic decisions. Suraniti SBled FGirault AFressinaud PMarre M Serum lipids and urinary albumin excretion in non-insulin-dependent diabetics.
Diabetes - A Major Risk Factor for Kidney Disease	This Feature Is Available To Subscribers Only Sign In or Create an Account. The three groups were similar in BMI, DBP, HDL and LDL cholesterol whereas age, DM duration, SBP, glycemic parameters FBS, HbA1c , and lipid parameters total cholesterol and triglycerides were significantly differed among three groups Table 1. Centers for Disease Control and Prevention. Related Coverage. Diabetic nephropathy affects the kidneys' usual work of removing waste products and extra fluid from the body. The large United Kingdom Prospective Diabetes Study 20 has not yet provided data on this issue.
Diabetes and Chronic Kidney Disease | CDC	Kidney failure is a life-threatening condition. Treatment options for kidney failure are dialysis or a kidney transplant. One of the important jobs of the kidneys is to clean the blood. As blood moves through the body, it picks up extra fluid, chemicals and waste. The kidneys separate this material from the blood. It's carried out of the body in urine. If the kidneys are unable to do this and the condition is untreated, serious health problems result, with eventual loss of life. In the early stages of diabetic nephropathy, there might not be symptoms. In later stages, symptoms may include:. Make an appointment with your health care professional if you have symptoms of kidney disease. If you have diabetes, visit your health care professional yearly or as often as you're told for tests that measure how well your kidneys are working. A typical kidney has about 1 million filtering units. Each unit, called a glomerulus, joins a tubule. The tubule collects urine. Conditions such as high blood pressure and diabetes harm kidney function by damaging these filtering units and tubules. The damage causes scarring. The kidneys remove waste and extra fluid from the blood through filtering units called nephrons. Each nephron contains a filter, called a glomerulus. Each filter has tiny blood vessels called capillaries. When blood flows into a glomerulus, tiny bits, called molecules, of water, minerals and nutrients, and wastes pass through the capillary walls. Large molecules, such as proteins and red blood cells, do not. The part that's filtered then passes into another part of the nephron called the tubule. The water, nutrients and minerals the body needs are sent back to the bloodstream. The extra water and waste become urine that flows to the bladder. The kidneys have millions of tiny blood vessel clusters called glomeruli. Glomeruli filter waste from the blood. Damage to these blood vessels can lead to diabetic nephropathy. The damage can keep the kidneys from working as they should and lead to kidney failure. Over time, diabetes that isn't well controlled can damage blood vessels in the kidneys that filter waste from the blood. This can lead to kidney damage and cause high blood pressure. High blood pressure can cause more kidney damage by raising the pressure in the filtering system of the kidneys. Diabetic nephropathy kidney disease care at Mayo Clinic. Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press. This content does not have an English version. This content does not have an Arabic version. Overview Diabetic nephropathy is a serious complication of type 1 diabetes and type 2 diabetes. How kidneys work. Request an appointment. Healthy kidney vs. diseased kidney Enlarge image Close. diseased kidney A typical kidney has about 1 million filtering units. Kidney cross section Enlarge image Close. Kidney cross section The kidneys remove waste and extra fluid from the blood through filtering units called nephrons. By Mayo Clinic Staff. Show references Diabetic kidney disease. National Institute of Diabetes and Digestive and Kidney Diseases. Accessed May 24, Diabetic kidney disease adult. Mayo Clinic; Mottl AK, et al. Diabetic kidney disease: Manifestations, evaluation, and diagnosis. Diabetes and chronic kidney disease. Centers for Disease Control and Prevention. Diabetic nephropathy. Merck Manual Professional Version. Goldman L, et al. Diabetes mellitus. In: Goldman-Cecil Medicine. Elsevier; The Saudi diabetic kidney disease study Saudi-DKD : Clinical characteristics and biochemical parameters. Ann Saudi Med 38 1 — International Society of Nephrology. Chapter 1: Definition and classification of CKD. Kidney Int Suppl 3 1 — Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: Synopsis of the kidney disease: Improving global outcomes clinical practice guideline update. Ann Intern Med 6 — Harjutsalo V, Groop PH. Epidemiology and risk factors for diabetic kidney disease. Adv Chronic Kidney Dis 21 3 —6. Al-Rubeaan K, Youssef AM, Subhani SN, Ahmad NA, Al-Sharqawi AH, Al-Mutlaq HM, et al. Diabetic nephropathy and its risk factors in a society with a type 2 diabetes epidemic: A Saudi national diabetes registry-based study. PloS One 9 2 :e American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care S8—S Early Treatment of Diabetic Retinopathy study research group. Grading diabetic retinopathy from stereoscopic colour fundus photographs-an extension of the modified airlie house classification. ETDRS report number Ophthalmology — Flack JM, Adekola B. Treands Cardiovasc Med 30 3 —4. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 9 — De Fronzo R. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes — Pecoits-Filho R, Abensur H, Betônico CC, Machado AD, Parente EB, Queiroz M, et al. Interactions between kidney disease and diabetes: Dangerous liaisons. Diabetol Metab Syndr Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol 12 12 — Kelly JT, Su G, Carrero JJ. Lifestyle interventions for preventing and ameliorating CKD in primary and secondary care. Curr Opin Nephrol Hypertens 30 6 — Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: A meta-analysis. Lancet —6. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Amorim RG, Guedes GDS, Vasconcelos SML, Santos JCF. Kidney disease in diabetes mellitus: Cross-linking between hyperglycemia, redox imbalance and inflammation. Arq Bras Cardiol 5 — Kebede SA, Tusa BS, Weldesenbet AB, Tessema ZT, Ayele TA. Incidence of diabetic nephropathy and its predictors among type 2 diabetes mellitus patients at university of gondar comprehensive specialized hospital, Northwest Ethiopia. J Nutr Metab , Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective, observational study. Tapp RJ, Shaw JE, Zimmet PZ, Balkau B, Chadban SJ, Tonkin AM, et al. Albuminuria is evident in the early stages of diabetes onset: Results from the Australian diabetes, obesity, and lifestyle study AusDiab. Am J Kidney Dis 44 5 —8. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: Inception cohort study. BMJ Wagnew F, Eshetie S, Kibret GD, Zegeye A, Dessie G, Mulugeta H, et al. Diabetic nephropathy and hypertension in diabetes patients of sub-Saharan countries: A systematic review and meta-analysis. BMC Res Notes 11 1 Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development and progression of nephropathy in type 2 diabetes: The united kingdom prospective diabetes study UKPDS Kidney Int 63 1 — Shen FC, Chen CY, Su SC, Liu RT. The prevalence and risk factors of diabetic nephropathy in Taiwanese type 2 diabetes - a hospital based study. ActaNephrologica 23 2 —5. Farah RI, Al-Sabbagh MQ, Momani MS, Albtoosh A, Arabiat M, Abdulraheem AM, et al. Diabetic kidney disease in patients with type 2 diabetes mellitus: A cross-sectional study. BMC Nephrol 22 1 :1—8. Agarwal R, Light RP. Physical activity and hemodynamic reactivity in chronic kidney disease. Clin J Am Soc Nephrol 3 6 —8. Bowlby W, Zelnick LR, Henry C, Himmelfarb J, Kahn SE, Kestenbaum B, et al. Physical activity and metabolic health in chronic kidney disease: A cross-sectional study. BMC Nephrol 17 1 Bai Y, Sigala W, Adams GR, Vaziri ND. Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease. Am J Nephrol 29 3 — Werner C, Fürster T, Widmann T, Pöss J, Roggia C, Hanhoun M, et al. Physical exercise prevents cellular senescence in circulating leukocytes and in the vessel wall. Nylen ES, Gandhi SM, Kheirbek R, Kokkinos P. Enhanced fitness and renal function in type 2 diabetes. Diabetes Med 32 10 —5. Macisaac RJ, Ekinci EI, Jerums G. Markers and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 63 2 :S39— Keywords: diabetic kidney disease DKD , diabetic nephropathy, longer duration of diabetes, risk factors, high prevalence of diabetes. Citation: Siddiqui K, George TP, Joy SS and Alfadda AA Risk factors of chronic kidney disease among type 2 diabetic patients with longer duration of diabetes. Received: 25 October ; Accepted: 14 November ; Published: 09 December Copyright © Siddiqui, George, Joy and Alfadda. This is an open-access article distributed under the terms of the Creative Commons Attribution License CC BY. The use, distribution or reproduction in other forums is permitted, provided the original author s and the copyright owner s are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. Top bar navigation. About us About us. Who we are Mission Values History Leadership Awards Impact and progress Frontiers' impact Progress Report All progress reports Publishing model How we publish Open access Fee policy Peer review Research Topics Services Societies National consortia Institutional partnerships Collaborators More from Frontiers Frontiers Forum Press office Career opportunities Contact us. Sections Sections. About journal About journal. Article types Author guidelines Editor guidelines Publishing fees Submission checklist Contact editorial office. ORIGINAL RESEARCH article Front. This article is part of the Research Topic Advances in Diabetic Kidney Disease: Pathophysiology, Clinical Characteristics, and Future Directions View all 10 articles. Risk factors of chronic kidney disease among type 2 diabetic patients with longer duration of diabetes. George 1 Salini S. Joy 1 Assim A. Alfadda 1,2,3. Introduction Diabetes mellitus DM is a chronic metabolic disorder characterized by elevated blood glucose level and associated with number of complications including acute metabolic and long-term vascular complications. Materials and methods Study population The data of the study population were collected retrospectively from a previous cohort study conducted at University Diabetes Center, King Saud University Medical City KSUMC , Riyadh, Saudi Arabia during the year 8. FE PubMed Abstract CrossRef Full Text Google Scholar. x PubMed Abstract CrossRef Full Text Google Scholar. Keywords: diabetic kidney disease DKD , diabetic nephropathy, longer duration of diabetes, risk factors, high prevalence of diabetes Citation: Siddiqui K, George TP, Joy SS and Alfadda AA Risk factors of chronic kidney disease among type 2 diabetic patients with longer duration of diabetes. Edited by: Mohammad H. Abukhalil , Al-Hussein Bin Talal University, Jordan.
Latest news	Factorrs access to newly published articles. Lifestyle rlsk for Diabetic nephropathy risk factors and Head lice treatment CKD in primary and secondary care. All rusk made substantial contributions to conception Diabetiv design, acquisition of data, or analysis and interpretation Enhancing gut function data; took part Diabrtic drafting the article fwctors Digestive benefits of high fiber foods it gactors Golf nutrition tips important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. How long does diabetic neuropathy take to develop? The in-depth study of these molecules and related pathways will help to further understand the mechanism of human DN progression, discover new therapeutic targets and explore new DN drugs.